Adagene (ADAG) vs Cartesian Therapeutics (RNAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Adagene (ADAG) has outperformed Cartesian Therapeutics (RNAC) over the past year, gaining 41.2% versus a loss of 31.4%. Over five years, ADAG leads with a -76.0% price change compared with -94.8% for RNAC. Cartesian Therapeutics is the larger company by market cap ($202.1 million vs $188.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | RNAC |
|---|---|---|
| Share price | $2.81 | $6.68 |
| Market cap | $188.67M | $202.11M |
| 1-day change | -4.10% | -1.04% |
| YTD return | +48.68% | -7.35% |
| 1-year return | +41.21% | -31.42% |
| 5-year return | -75.98% | -94.79% |
| EPS (TTM) | $-0.37 | $-5.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.85 | $11.00 |
| 52-week low | $1.30 | $5.60 |
| Distance from 52-week high | -42.06% | -39.27% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +252.67% | +404.04% |
| Average volume | 246.37K | 132.71K |
| Shares outstanding | 67.14M | 30.26M |
| Employees | 128 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed RNAC by 72.6 percentage points over the past year.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
ADAG vs RNAC FAQ
Which is bigger, Adagene or Cartesian Therapeutics?
Cartesian Therapeutics (RNAC) is larger, with a market capitalization of $202.11M compared with $188.67M for Adagene (ADAG).
Which stock has performed better over the past year, ADAG or RNAC?
ADAG returned +41.21% over the past 12 months, compared with -31.42% for RNAC (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and Cartesian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.